That's exactly what your consultation is for: our medical providers determine the correct, personalized protocol for you and keep it safe as things change
In order to fuel global expansion, companies are investing in developing new drugs in sustained release and oral modality, add capacity for production, enhance patient support programs, and write applications for regulatory approval of additional indications
Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study)
service as a consultant for AstraZeneca, Bayer Healthcare Pharmaceuticals, Biomea Fusion, Boehringer Ingelheim, Carmot, Eli Lilly, Intarcia, Intercept Pharmaceuticals, Janssen Global Services, Johnson & Johnson Medical Devices & Diagnostics GroupLatin America, MannKind Corporation, Merck, Novo Nordisk, Pfizer, Sanofi US Services, Shionogi, Structure Therapeutics, Target Pharma, Valeritas and Zealand Pharma A/S
